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ABSTRACT: Three series of biarylpyrazole imidazole and triazoles are described, 
which vary in the linker between the biaryl pyrazole and imidazole/triazole group. 
The imidazole and triazole series with the short –CH2- linker displayed promising 
antimycobacterial activity, with the imidazole–CH2- series (7) showing low MIC 
values (6.25-25 g/mL), which was also influenced by lipophilicity. Extending the 
linker to –C(O)NH(CH2)2- resulted in loss of antimycobacterial activity. Binding 
affinity of the compounds with CYP121A1 was determined by UV-visible optical 
titrations with KD values of 2.63, 35.6 and 290 M, respectively, for the tightest 
binding compounds 7e, 8b and 13d from their respective series. Both binding affinity 
assays and docking studies of the CYP121A1 inhibitors suggests type II indirect 
binding through interstitial water molecules, with key binding residues Thr77, Val78, 
Val82, Val83, Met86, Ser237, Gln385 and Arg386, comparable with the binding 
interactions observed with fluconazole and the natural substrate dicyclotyrosine.  
 
 
 
 
 
 
 
 
 
 
 
 
 3 
INTRODUCTION 
Tuberculosis (TB) is endemic in numerous countries of the developing world, and 
serious issues are caused by infection with drug- (and multidrug-) resistant strains of 
the causative bacterium Mycobacterium tuberculosis (Mtb) and by the common 
occurrence of HIV co-infection as a result of the high susceptibility of 
immunocompromised individuals to TB infection.1,2 The global impact of TB is 
evident from World Health Organization data which reported that, in 2015, 1.8 
million people died from TB and approximately 2 billion people, a third of the 
world’s population, were infected with latent TB.2 This disease has a global impact 
and the “deadly synergy” of co-infection with TB and HIV has serious life-limiting 
consequences for individuals who do not receive the relevant therapeutics in a timely 
manner.1,2 
Challenges associated with the current antibiotic therapy include drug 
intolerances and toxicities; pharmacokinetic drug-drug interactions, particularly with 
ART drugs in patients co-infected with HIV; and patient adherence given the lengthy 
treatment regimens.2 The most effective drugs in clinical use have been isoniazid, the 
first oral mycobactericidal drug, and rifampicin. The combined used of rifampicin and 
pyrazinamide shortened TB chemotherapy to 9 and 6 months respectively.3,4 Drug-
resistant strains of Mtb fall into three main categories: multidrug resistant (MDR) TB, 
a form of TB caused by bacteria that do not respond to at least isoniazid and 
rifampicin, the two most powerful first-line anti-TB drugs; extremely drug resistant 
(XDR) TB, a form of MDR tuberculosis that responds to even fewer available 
medicines, including the most effective second-line anti-TB drugs; and totally drug 
resistant (TDR) TB, which describes strains of Mtb that are resistant to all available 
first and second-line anti-TB drugs.1,2,5 
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MDR-TB is now a major problem globally and threatens the ability to treat 
and control TB infection. In 2015, an estimated 480,000 people developed MDR-TB, 
resulting in 190,000 deaths.1 Treatment should be “individualised”, based on drug 
susceptibility testing (DST). However, this is not always possible and treatment is 
usually based on the pattern of drug resistance in the local geographical region. MDR-
TB requires longer treatment (18-24 months) with drugs that are more toxic and less 
efficacious. Worldwide, MDR-TB treatment success rates are as low as 50%.5 XDR-
TB requires third-line anti-TB drugs, which are expensive and are often associated 
with more severe side effects. The emergence of MDR-, XDR- and TDR-TB strains 
has led to intensified research to identify new anti-TB drugs over the past decade.  
Mycobacterium tuberculosis encodes twenty cytochrome P450 enzymes 
(CYPs or P450s). One of these is CYP121A1, which was shown to be essential for 
microbial viability.6 CYP121A1 catalyses the formation of an unusual intra-molecular 
bond between carbon atoms in the ortho-positions of two tyrosine groups in the 
cyclodipeptide dicyclotyrosine (cYY), the natural substrate, to form the metabolite 
mycocyclosin. cYY interacts indirectly with the heme iron through water molecules 
(Figure 1A). Interestingly, this type of indirect binding mode was also observed in the 
crystal structure of CYP121A1 bound to the azole antifungal drug fluconazole.7 The 
crystal structure of the CYP121A1/fluconazole complex, PDB 2IJ7, exhibits dual 
fluconazole conformations (I and II). In the indirect conformation (I), a triazole 
nitrogen of fluconazole binds to the heme iron via a distal water molecule that 
remains coordinated to the heme iron. However, in the direct conformation (II) the 
fluconazole binds through a triazole nitrogen directly to the heme iron (Figure 1B). 
While both binding modes are evident, the indirect binding (via water) mode appears 
predominant in this structure.8  
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Figure 1. Crystal structures of CYP121A1 co-crystallized with (A) cYY (PDB 3GH), and (B) 
fluconazole (PDB 2IJ7). Both the natural substrate and fluconazole interact indirectly with the 
heme via interstitial water molecules with key amino acids identified. 
 
 
The natural substrate cYY binds to the CYP121A1 active site without 
inducing any significant change in the P450 structure, consistent with it being a good 
substrate for the enzyme.6 Through crystallization of ligand complexes it was 
discovered that iodopyrazole binds with its pyrazole group in a channel between P450 
helices F and G, and “stacked” between Trp182 and Phe168 side chains. The iodine 
atom protrudes towards the active site and interacts with hydrophobic amino acids.7 In 
designing potential new inhibitors of CYP121A1, we noted that ‘Y’-shaped molecules 
might provide a good “fit” within the P450 active site. This may be the result of a 
high conformational energy barrier necessary for binding to CYP121A1. 
Using this observation to help design novel CYP121A1 inhibitors, our 
research explores the CYP121A1 binding and anti-mycobacterial activity of various 
‘Y-shaped’ biaryl pyrazole imidazole or triazole derivatives (Figure 2). Using 
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different linkers between the hydrophobic biaryl pyrazole moiety (blue, Figure 2) and 
the heme binding azole group (red, Figure 2) the proximity of the heme binding 
moiety will be extended to determine if this has an effect on indirect/direct binding of 
new ligands to the heme iron.  
  
Figure 2. General structure of ‘Y-shaped’ biaryl pyrazole, imidazole and triazole derivatives 
showing different linkers. 
 
RESULTS AND DISCUSSION 
   Chemistry. The imidazole (7) or triazole (8) pyrazole compounds were obtained via 
a five-step synthetic route (Scheme 1) beginning with the preparation of the imines 
(3) on reaction of acetophenones (1) with phenylhydrazine under acidic conditions.9,10 
The aldehydes (4) were prepared as previously described9,10 by a Vilsmeier-Haack 
reaction of the imines (3). Reduction of the aldehydes (4) with NaBH4 resulted in high 
yields of the corresponding alcohols (5), which were subsequently converted to the 
chlorides (6) on treatment with thionyl chloride in toluene at 115 oC for 2 h.11 The 
chlorides were generally found to be unstable so were prepared immediately before 
use in the following step. Reaction of the chlorides (6) with either the potassium salt 
of imidazole or triazole, prepared in situ by treatment of imidazole or triazole with 
potassium carbonate in acetonitrile at 45 oC for 1 h, overnight at 70 oC, gave the 
required final imidazole (7) and triazole (8) pyrazole derivatives (Scheme 1). 
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Scheme 1. Reagents and Conditions: (i) AcOH, r.t., 15 min (ii) AcOH, EtOH, 80 oC, 1 h (iii) 
POCl3, DMF, 90 °C, 2 h (iv) NaBH4, EtOH, r.t. 1 h (v) SOCl2, toluene, 115 oC, 2 h (vi) 
imidazole, K2CO3, CH3CN, 45 oC, 1 h then 70 oC, overnight (vii) imidazole, K2CO3, CH3CN, 
45 oC, 1 h then 70 oC, overnight. [a, R = H; b, R = 4-F; c, R = 4-Cl; d R = 4-CH3; e, R = 4-
OCH3; f, R = 4-Br; g, R = 4-I; h, R = 4-CN]. 
 
 
The ‘extended’ pyrazole compounds were prepared from the aldehydes (4). 
Oxidation to the carboxylic acids (9) was achieved on treatment of the aldehydes (4) 
with potassium permanganate (Scheme 2).12 To prepare the aminoethylimidazole 
dihydrochloride salt (12) the corresponding 2-(2-(1H-imidazol-1-yl)ethyl)isoindoline-
1,3-dione (11) was required. The isoindoline-1,3-dione was prepared following the 
procedure of Popkov and Skvortsova,13 which involved melted imidazole refluxed 
with bromoethylphthalamide (10) and potassium iodide, resulting in the desired 
product (11) in 49 % yield after recrystallisation from isopropanol. The isoindole-1,3-
dione was then treated with hydrazine following the Ing-Manske procedure to give 
the required  aminoethylimidazole dihydrochloride (12) in 82 % yield (Scheme 2).  
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Scheme 2. Reagents and Conditions: (i) KMnO4, tBuOH-H2O, 75 oC, 45 min (ii) imidazole, 
100 oC, 3 h then toluene, 115 oC, 20 h (iii) NH2NH2, EtOH, reflux, 4 h (iv) CDI, DMF, 1 h 
then 12, Et3N, DMF, r.t., 20 h. [a, R = H; b, R = 4-F; c, R = 4-Cl; d R = 4-CH3; e, R = 4-
OCH3]. 
 
The final amides (13) were prepared by a carbonyldiimidazole (CDI) coupling 
reaction through coupling of the carboxylic acids (9) with the free amine, generated in 
situ on treatment of the aminoethylimidazole dihydrochloride salt (13) with 
triethylamine in DMF. The final amide derivatives (13) were obtained in low to 
moderate yields (Scheme 2).  
CYP121A1 Ligand Binding Affinity. The CYP121A1 binding affinity (Kd) of the 
various compounds was determined by UV-vis optical titration. Results shown in 
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Tables 1, 2 and 3 reveal that most of the compounds show a red (type II) shift in the 
Soret peak position (Figure 3, for example 7b), indicating that, in the solution state, 
most of these compounds coordinate either (i) directly to the CYP121A1 heme iron or 
(ii) indirectly to the heme iron through interstitial water molecule(s). Another 
possibility is (iii) that a ligand binding distant from the heme does not induce a heme 
spectral shift (but would block the active site).  
 
Table 1.  KD and MIC values for series 7 against M. tuberculosis H37Rv 
 
Compound R KD (M) Soret peak shift 
(nm) 
MIC 
(g/mL) 
7a H 2.63 ± 0.19 416 to 423.5 12.5 
7b F 4.16 ± 0.47 416 to 423.5 25 
7c Cl 7.42 ± 0.66 416 to 422 12.5 
7d CH3 5.36 ± 0.59 416 to 421.5 12.5 
7e OCH3 11.4 ± 0.9 416 to 421 25 
7f Br 19.5 ± 0.2 416 to 420 6.25 
7g I 13.6 ± 0.2 416 to 422 6.25 
7h CN 45.9 ± 0.6 416 to 418 100 
Fluconazole  8.6 ± 0.2  >100 
Clotrimazole  0.07 ± 0.01  20 
cYY  5.82 ± 0.16  - 
 
Series 7 (imidazole deriviatives) showed the highest affinity for CYP121A1, 
with compounds 7a-e having Kd values < 12 M (KD = 2.63 ± 0.19, 4.16 ± 0.47, 7.42 
± 0.66, 5.36 ± 0.59, and 11.35 ± 0.94 M, respectively) (Table 1). The values are 
comparable to the KD values for the azole drugs ketoconazole (imidazole) and 
fluconazole (triazole), which are 3.3 ± 0.3 and 8.6 ± 0.2 M, respectively. 
Compounds 7a and 7b induce the most extensive Soret absorbance shifts (416 to 
423.5 nm), suggesting that the CYP121A1 heme iron is predominantly coordinated by 
a direct imidazole nitrogen bond in these cases. Compounds 7c to 7h show less 
extensive Soret red shifts on binding the CYP121A1 heme, suggesting that ligation 
modes in these cases may involve imidazole nitrogen interactions with heme iron 
mediated through an interstitial water ligand, and that these could occur to a greater 
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(e.g. compounds 7f and 7h) or lesser (e.g. compounds 7c and 7g) extent. The smallest 
Soret shift occurs with compound 7h (416 to 418 nm) and it is likely that indirect 
coordination though the retained distal water on the heme iron is predominant in this 
case. However, alternative active site binding poses made by series 7 ligands that do 
not impact on the heme iron or its distal water ligand cannot be ruled out at this stage, 
and this phenomonen could also provide explanations for the less extensive Soret 
shifts induced by a number of the series 7 molecules. 
 
Figure 3. UV-Vis optical binding titration for compound 7b binding to CYP121A1. The 
left hand panel shows data from a compound 7b titration with CYP121A1 (~4.7 M) with the 
ligand-free spectrum as a thick black line, spectra following progressive additions of 7b as 
thin solid lines, and the final near-saturated protein spectrum shown as a thick red line. The 
inset shows overlaid difference spectra generated by the subtraction of the starting spectrum 
from each consecutive ligand-bound spectrum collected in the titration. The right hand panel 
shows a plot of compound 7b-induced absorbance change – calculated as the difference 
between the peak and trough in the difference spectra in the left hand panel, using the same 
wavelength pair (429 and 392 nm, respectively) throughout. Data were fitted using the Hill 
equation to give a 7b KD value of 4.16 ± 0.47 M. 
 
Series 8 (triazole derivatives) has affinities ranging from KD = 35.6 ± 2.7 M 
(compound 8b) to 193 ± 21 M (compound 8f) (Table 2). Series 13 (pyrazole amide 
derivatives) had weaker affinity, with moderate KD values between 290 and 400 M 
(290 ± 27, 314 ± 43 and 394 ± 39 M for compounds 13d, 13e and 13a, respectively). 
No evidence of binding was observed for halogenated derivatives of this compound 
class (Table 3). As was also observed for series 7, the extent of the CYP121A1 heme 
 11 
Soret shift observed at apparent saturation with the series 8 compounds varied 
considerably. In series 8, a similar pattern of Soret shifts was observed to that seen 
with series 7, with peak shifts as small as 416 to 417.5 nm (compound 8f), and as 
large as 416 to 423 nm (compound 8b). Again, we infer that the most extensive 
absorbance changes occur for those ligands that show predominantly direct 
coordination of heme iron through a triazole nitrogen (i.e. compounds 8a and 8b), 
while less extensive Soret shifts (i.e. compounds 8d and 8f) are likely indicative of 
either indirect (through the heme distal water) coordination of the CYP121A1 heme 
iron, or possibly result from mixed binding poses that include modes that do not 
influence the heme spectrum. For series 13, ligand binding curves were obtained for 
the compounds 13a, 13d and 13e. However, the extents of Soret band shift were 
modest (416 to 417.5/418 nm). Once again, these data suggest either indirect 
coordination of heme iron through an imidazole nitrogen or a combination of this type 
of ligand binding mode with other pose(s) that do not impact on the heme spectrum. 
 
Table 2.  KD and MIC values for series 8 against M. tuberculosis H37Rv 
 
Compound R KD (M) Soret peak shift 
(nm) 
MIC 
(g/mL) 
8a H 73.5 ± 0.7 416 to 422 50 
8b F 35.6 ± 2.7  416 to 423 25 
8c Cl 83.8 ± 7.4 416 to 421 25 
8d CH3 187 ± 13 416 to 418 >100 
8e OCH3 96.5 ± 8.4 416 to 420 25 
8f Br 193 ± 21 416 to 417.5 25 
8g I - No binding 50 
8h CN - No binding >100 
 
 
Azole antifungal drugs (clotrimazole, econazole, fluconazole, ketoconazole 
and miconazole) bind tightly to Mtb CYP121A1, inducing a Soret peak shift to 
between 421-423.5 nm. The KD values for clotrimazole, econazole and miconazole 
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are all < 0.2 μM, indicating very tight binding, and as determined from data fitting 
using the Morrison (quadratic) equation.14 
 
Table 3.  KD and MIC values for series 13 against M. tuberculosis H37Rv 
 
Compound R KD (M) Soret peak shift 
(nm) 
MIC 
(g/mL) 
13a H 394 ± 39 416 to 417.5 >100 
13b F - No binding >100 
13c Cl - No binding >100 
13d CH3 290 ± 27 416 to 417.5 >100 
13e OCH3 314 ± 43 416 to 418 100 
 
 
MIC determination against Mycobacterium tuberculosis. The derivatives were 
screened against M. tuberculosis H37Rv by the REMA (Resazurin Microtiter Assay) 
method.15 In the imidazole (7) and triazole (8) pyrazole compounds, the imidazoles 
(7) were generally more inhibitory to M. tuberculosis growth and displayed better 
activity than the triazoles (8) (Tables 1 and 2), with the 4-bromo (7f) and 4-iodo (7g) 
derivatives displaying good activity (MIC 6.25 g/mL). All the imidazoles (7), with 
the exception of the 4-nitrile derivative (7h, MIC90 = 100 g/mL), were significantly 
more active than the azole drug fluconazole. Compounds 7a-d, 7f and 7g are more 
active than clotrimazole (MIC90 = 20 g/mL) (Table 1). The ‘extended’ pyrazole 
compounds 13a-e had little antimicrobial activity (MIC90 ≥100 g/mL) (Table 3). 
Molecular Modelling and Crystallography  
The Molecular Operating Environment (MOE) program16 was used to perform 
molecular docking and was found to closely replicate the position and binding 
interactions of cYY and fluconazole, as observed in the crystal structures PDB 3G5H 
and PDB 2IJ7 respectively. 
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Figure 4. Molecular modelling of selected compounds. (A) The triazole group of 8b interacts 
with the heme indirectly via an interstitial water molecule and binds in a similar 
conformation, and with the same key amino acids, as that observed for cYY and fluconazole. 
(B) The nitrile derivative 7h binds in a different conformation with the nitrile bound to water 
molecules and held in a position further away from the heme active site. (C) The amide 
imidazole 13b also interacts with the heme via an interstitial water molecule, but its greater 
flexibility also resulted in various other conformations. 
 
The imidazole (7) and triazole (8) compounds were all found to interact with 
the heme through an interstitial water molecule via hydrogen bonding interactions 
with Ser237, Gln 385 and Arg386 on one side of the structure, whilst on the other side 
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of the structure interactions are through hydrophobic amino acid residues including 
Thr77, Val78, Val82, Val83, Met86 (Figure 4A). The docking results were consistent 
with the type II binding indicated from the binding affinity assays. The only exception 
was the nitrile substituted derivatives 7h and 8h. In both cases the nitrile group 
interacted with Ala167 and Trp182 via interstitial water molecules, holding the 
compounds away from the active site with the imidazole/triazole ring positioned away 
from the heme group (Figure 4B). 
The amide imidazole compounds (13) were positioned in a similar manner 
(Figure 4C) to 7 and 8. However, whereas the imidazole (7) and triazole (8) were 
consistently positioned within the active site, numerous conformations were observed 
for the amide imidazole series (13), possibly owing to their increased conformational 
flexibility, which may correlate with the moderate binding affinity observed. 
 
A B 
  
Figure 5. X-ray crystal structures of (A) 7b and (B) 7e binding to CYP121A1.  
 
Two compounds were successful co-crystallized with CYP121A1, 7b and 7e 
(Figure 5). However, the crystallized structures did not correlate with the binding 
affinity results as the imidazole group was positioned away from the heme group and 
in both cases the compounds were located in positions too far away to form direct or 
indirect binding interactions with the heme iron. However, the observed binding poses 
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of 7b and 7e are similar and both clearly result in effective blockage of the active site 
and thus inhibition of binding of the cYY substrate. These data illustrate how 
different P450 ligand binding modes can be adopted by molecules bound to proteins 
in the solution state or in the more constrained environment of protein crystals. In the 
case of the compound series investigated in this study, there is clear evidence from 
structural, molecular modelling and UV-visible ligand titration studies for the 
adoption of binding modes that involve direct or indirect (via the distal water ligand) 
coordination of the heme iron by imidazole or triazole nitrogens, as well as for modes 
in which the bound ligands are distant from the heme and are unlikely to influence the 
CYP121A1 heme spectrum. 
 
Conclusion 
The data presented demonstrate the successful binding to CYP121A1 of a range of 
different compounds inspired by the structure of CYP121A1’s natural substrate (the 
cyclic dipeptide cYY). Series 7 produced the most effective antimycobacterial agents 
with the tightest binding constants, and with KD values for the eight compounds in 
this series in the range between 2.63-45.9 M, with an average (mean) KD value of 
~13.7 M. The series 7 compounds with the best MIC values were those with bromo 
(7f) and iodo (7g) substituents (MIC = 6.25 g/mL), Hansch analysis suggested that 
increased lipophilicity (Figure 6) may correlate with improved antimycobacterial 
activity in this series, possibly through facilitating increased drug uptake across the 
Mtb lipid-rich cell wall (Table 1).  
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Figure 6. Hansch analysis illustrating correlation between MIC and calculated LogP17 values 
for the imidazole compounds (7) (the nitrile 7h is excluded as an outlier). 
 
The 4-nitrile derivative 7h is a relatively weak binder (KD = 45.9 M), a property 
which may be explained from molecular docking (Figure 4B) where the nitrile 
interacts with Ala167 and Trp182 via interstitial water molecules, holding the 
compound at a distance too far from the active site to attain indirect or direct 
interaction with the heme.  
From the antimicrobial MIC data, it is clear that extending the “linker” region of the 
pyrazole derivatives from –CH2- (series 7 and 8) to -C(O)NH-(CH2)2- (series 13) does 
not translate to improved MIC values. Computational docking studies suggested that 
these extended compounds (series 13) were able to interact with the heme indirectly 
and fit within the hydrophobic CYP121A1 pocket. However, only moderate KD 
values between 290 and 400 M were observed for compounds 13d, 13e and 13a, 
respectively, with only partial type II heme shifts (from 416 nm to 417.5/418 nm). 
There was also no evidence of binding for halogenated derivatives of this compound 
class. 
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EXPERIMENTAL SECTION 
General Procedures. All reagents and solvents were of general purpose or 
analytical grade and purchased from Sigma-Aldrich Ltd, Fisher Scientific, Fluka and 
Acros. 1H and 13C NMR spectra were recorded with a Bruker Avance DPX500 
spectrometer operating at 500 and 125 MHz, with Me4Si as internal standard. Mass 
spectra (HRMS) were determined by the EPSRC mass spectrometry centre (Swansea, 
UK). Elemental analysis was performed by MEDAC Ltd (Chobham, Surrey, UK). 
Flash column chromatography was performed with silica gel 60 (230-400 mesh) 
(Merck) and TLC was carried out on precoated silica plates (kiesel gel 60 F254, BDH). 
Compounds were visualised by illumination under UV light (254 nm) or by the use of 
vanillin stain followed by heating. Melting points were determined on an 
electrothermal instrument and are uncorrected. All solvents were dried prior to use 
and stored over 4 Å molecular sieves, under nitrogen. All the compounds were ≥ 95% 
pure. 
The imines (3), aldehydes (4), alcohols (5), chlorides (6), carboxylic acids (9) and 1-
(2-ammonioethyl)-1H-imidazol-3-ium chloride (12) were prepared as previously 
described.9-13 All compounds were more than 95% pure. 
General method for the preparation of imidazole and triazole derivatives 
(7) and (8). To a stirred suspension on K2CO3 (3 mmol) in dry acetonitrile (20 mL) 
was added imidazole (3 mmol) or triazole (3 mmol). The reaction mixture was 
refluxed at 45 °C for 1 h. After cooling to room temperature the chloromethyl 
pyrazole compound (6) (0.76 mmol) was added and the reaction mixture refluxed at 
70 °C overnight. The solvent was evaporated under reduced pressure and the resulting 
mixture diluted with EtOAc (50 mL) and washed with H2O (3 x 20 mL). The EtOAc 
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layer was dried (MgSO4) and evaporated under reduced pressure to give the crude 
imidazole (7) or triazole (8) which was was further purified by recrystallisation. 
(1,3-Diphenyl)-4-((1,3-imidazol-1-yl)methyl)-1H-pyrazole (7a). Prepared 
from 4-(chloromethyl)-1,3-diphenyl-1H-pyrazole (6a) (0.35 g, 1.3 mmol). Product 
obtained as a yellow crystalline solid after recrystallization from methanol, yield 0.12 
g (32 %). M.p. 124-128 oC. TLC (3:1 petroleum ether/EtOAc), Rf = 0.06. 1H NMR 
(CDCl3): 7.85 (s, 1H, pyrazole), 7.74 (d, J = 7.7 Hz, 2H, triazole), 7.68 (s, 1H, Ar), 
7.61 (d, J = 7.0 Hz, 2H, Ar), 7.42-7.50 (m, 5H, Ar), 7.33 (t, J = 7.5 Hz, 1H, Ar), 7.12 
(s, 1H, Ar), 6.96 (s, 1H, Ar), 5.26 (s, 2H, CH2). 
13C-NMR (CDCl3): 151.4, 116.2 (2 
x pyrazole), 139.6, 132.4 (2 x Ar), 136.9, 129.5, 129.3, 128.9, 128.6, 127.9, 127.7, 
126.4, 119.1, 119.0 (12 x CH, Ar), 41.9 (CH2). Anal. Calcd for C19H16N4 (300.36): C, 
75.98; H, 5.37; N, 18.64. Found: C, 76.10; H, 5.39; N, 18.58. 
4-((1H-Imidazol-1-yl)methyl)-3-(4-fluorophenyl)-1-phenyl-1H-pyrazole 
(7b). Prepared from 4-(chloromethyl)-3-(4-fluorophenyl)-1-phenyl-1H-pyrazole (6b) 
(0.22 g, 0.76 mmol). Product obtained as a yellow crystalline solid after 
recrystallization from EtOH-H2O 1:1 v/v, yield 0.07 g (29 %). M.p. 128-130 
oC. TLC 
(3:1 petroleum ether/EtOAc), Rf = 0.06. 1H NMR (CDCl3): 7.89 (s, 1H, pyrazole), 
7.78 (s, 1H, Ar), 7.73 (d, J = 7.8 Hz, 2H, Ar), 7.55-7.58 (m, 2H, Ar), 7.49 (t, J = 7.7 
Hz, 2H, Ar), 7.34 (t, J = 7.5 Hz, 1H, Ar), 7.13-7.18 (m, 3H, Ar), 6.95 (s, 1H, Ar), 5.25 
(s, 2H, CH2). 
13C-NMR (CDCl3): 164.0, 150.6, 139.5 (3 x C, Ar), 162.0, 128.5 (2 x 
C, pyrazole), 136.8, 129.7, 129.6, 128.9, 128.0, 127.0, 117.1, 117.0, 116.0, 115.8 (13 
x CH, Ar), 41.9 (CH2). Anal. Calcd for C19H15FN4 (318.35): C, 71.68; H, 4.75; N, 
17.60. Found: C, 71.51; H, 4.98; N, 17.62. 
4-((1H-Imidazol-1-yl)methyl)-3-(4-chlorophenyl)-1-phenyl-1H-pyrazole 
(7c). Prepared from 4-(chloromethyl)-3-(4-chlorophenyl)-1-phenyl-1H-pyrazole (6c) 
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(0.91 g, 3 mmol). Product obtained as a yellow crystalline solid after recrystallization 
from ethanol, yield 0.52 g (52 %). M.p. 155-158 oC. TLC (3:1 petroleum 
ether/EtOAc), Rf = 0.05. 1H NMR (CDCl3): 7.88 (s, 1H, pyrazole), 7.78 (s, 1H, Ar), 
7.73 (d, J = 8.4 Hz, 2H, Ar), 7.54 (d, J = 8.0 Hz, 2H, Ar), 7.49 (d, J = 7.6 Hz, 2H, 
Ar), 7.45 (d, J = 8.1 Hz, 2H, Ar), 7.35 (t, J = 7.4 Hz, 1H Ar), 7.14 (s, 1H, Ar), 6.96 (s, 
1H, Ar), 5.26 (s, 2H, CH2). 
13C-NMR (CDCl3): 150.3, 116.0 (2 x C, pyrazole), 
139.5, 134.6, 130.8 (3 x C, Ar), 136.8, 129.6, 129.1, 129.0, 128.1, 127.1, 119.1, 119.0 
(12 x CH, Ar), 41.9 (CH2). Anal. Calcd for C19H15ClN4 (334.80): C, 68.16; H, 4.52; 
N, 16.73. Found: C, 68.09; H, 4.17; N, 16.58. 
4-((1H-Imidazol-1-yl)methyl)-1-phenyl-3-(p-tolyl)-1H-pyrazole (7d). 
Prepared from 4-(chloromethyl)-1-phenyl-3-(p-tolyl)-1H-pyrazole (6d) (0.35 g, 1.24 
mmol). Product obtained as a yellow-orange crystalline solid after recrystallization 
from EtOH-H2O 1:1 v/v, yield 0.065 g (17 %). M.p. 145-148 
oC. TLC (3:1 petroleum 
ether/EtOAc), Rf = 0.05. 1H NMR (CDCl3): 7.87 (s, 1H, pyrazole), 7.8 (s, 1H, Ar), 
7.74 (d, J = 8.3 Hz, 2H, Ar), 7.48-7.50 (m, 4H, Ar), 7.28-7.34 (m, 4H, Ar), 7.13 (s, 
1H, Ar), 6.95 (s, 1H, Ar), 5.27 (s, 2H, CH2), 2.43 (s, 3H, CH3). 
13C-NMR (CDCl3): 
151.5, 115.9 (2 x C, pyrazole), 139.7, 138.5, 129.4 (3 x C, Ar), 136.8, 129.6, 129.5, 
128.6, 127.8, 127.7, 126.8, 119.1 (13 x CH, Ar), 42.0 (CH2), 21.3 (CH3). Anal. Calcd 
for C20H18N4 (314.38): C, 76.41; H, 5.77; N, 17.81. Found: C, 76.40; H, 5.79; N, 
17.77. 
4-((1H-Imidazol-1-yl)methyl)-3-(4-methoxyphenyl)-1-phenyl-1H-pyrazole 
(7e). Prepared from 4-(chlorophenyl)-3-(4-methoxyphenyl)-1-phenyl-1H-pyrazole 
(6e) (0.88g, 2.9 mmol). Product obtained as a white crystalline solid after 
recrystallization from EtOH-H2O 1:1 v/v, yield 0.42 g (43 %). M.p. 102-106 
oC. TLC 
(3:1 petroleum ether/EtOAc), Rf = 0.05. 1H NMR (CDCl3): 7.89 (s, 1H, pyrazole), 
 20 
7.85 (s, 1H, Ar), 7.74 (d, J = 7.6 Hz, 2H, Ar), 7.52 (d, J = 8.8 Hz, 2H, Ar), 7.48 (d, J 
= 7.5 Hz, 2H, Ar), 7.32 (t, J = 7.5 Hz, 1H, Ar), 7.14 (s, 1H, Ar), 7.01 (d, J = 8.8 Hz, 
2H, Ar), 6.96 (s, 1H, Ar), 5.27 (s, 2H, CH2), 3.88 (s, 3H, OCH3). 
13C-NMR (CDCl3): 
159.9, 139.7, 124.8 (3 x C, Ar), 151.4, 115.6 (2 x C, pyrazole), 136.8, 129.5, 129.1, 
128.5, 127.5, 126.8, 119.0, 114.4 (13 x CH, Ar), 55.4 (CH3), 42.1 (CH2). Anal. Calcd 
for C20H18N4O (330.39): C, 71.68; H, 4.75; N, 17.60. Found: C, 71.66; H, 4.76; N, 
17.54. 
4-((1H-Imidazole-1-yl)methyl)-3-(4-bromophenyl)-1-phenyl-1H-pyrazole  
(7f). Prepared from (4-(chloromethyl)-3-(4-bromophenyl)-1-phenyl-1H-pyrazole) (6f) 
(0.75 g, 2.2 mmol). Product obtained as a white crystalline solid after recrystallization 
from EtOH-H2O 1:1 v/v, yield 0.45 g (56 %). M.p. 161-163 
oC. TLC (9:1 
CH2Cl2/MeOH), Rf = 0.83. 
1H NMR (CDCl3): 8.60 (s, 1H, pyrazole), 8.15 (s, 1H, 
imidazole), 7.75 (d, J = 7.6 Hz, 2H, Ar), 7.60 (d, J = 8.4 Hz, 2H, Ar), 7.5-.47 (m, 4H, 
Ar), 7.35 (t, J = 7.4 Hz, 1H, Ar), 7.20 (s, 1H, imidazole), 6.90 (s, 1H, imidazole), 5.43 
(s, 2H, CH2). 
13C-NMR (CDCl3): 150.2 (C, pyrazole), 139.5 (C, Ar), 137.0 (CH, 
imidazole), 132.0 (2 x CH, Ar), 131.3 (C, Ar), 130.0 (CH, Ar), 129.6 (C, Ar), 129.3 
(CH, imidazole), 127.9 (2 x CH, Ar), 127.1 (2 x CH, Ar), 122.8 (CH, pyrazole), 119.1 
(2 x CH, Ar), 118.9 (CH, imidazole), 116.4 (C, pyrazole), 41.7 (CH2). Anal. Calcd for 
C19H15N4Br (379.25): C, 60.17; H, 3.99; N, 14.77. Found: C, 59.92; H,  4.02; N, 
14.67. 
4-((1H-Imidazole-1-yl)methyl)-3-(4-iodophenyl)-1-phenyl-1H-pyrazole 
(7g). Prepared from (4-(chloromethyl)-3-(4-iodophenyl)-1-phenyl-1H-pyrazole) (6g) 
(0.75 g, 1.9 mmol). Product obtained as a pale yellow crystalline solid after 
recrystallization from EtOH-H2O 1:1 v/v, yield 0.45 g (55 %). M.p. 169-173 
oC. TLC 
(3:2 petroleum ether/EtOAc), Rf = 0.08. 1H NMR (CDCl3): 8.10 (s, 1H, pyrazole), 
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7.90 (s, 1H, imidazole), 7.80 (d, J = 8.5 Hz, 2H, Ar), 7.74 (m, 3H, Ar) 7.16 (s, 1H, 
imidazole), 6.95 (s, 1H, imidazole), 5.32 (s, 2H, CH2). 
13C-NMR (CDCl3): 150.3 (C, 
pyrazole), 139.5 (C, Ar), 138.0 (2 x CH, Ar), 137.0 (CH, imidazole), 131.9 (C, Ar), 
130.0 (CH, Ar), 129.6 (CH, imidazole), 129.5 (2 x CH, Ar), 127.9 (2 x CH, Ar), 127.1 
(CH, pyrazole), 119.1 (2 x CH, Ar), 118.9 (CH, imidazole), 116.4 (C, pyrazole), 94.4 
(C, C-I), 41.7 (CH2). Anal. Calcd for C19H15N4I (426.25): C, 53.54; H, 3.55; N, 13.14. 
Found: C, 53.74; H,  3.23; N, 13.15. 
4-(4-((1H-Imidazol-1-yl)methyl)-1-phenyl-1H-pyrazol-3-yl)benzonitrile 
(7h). Prepared from 4-(4-(chloromethyl)-1-phenyl-1H-pyrazol-3-yl)benzonitrile (6h) 
(0.75 g, 2.5 mmol). Product obtained as a pale yellow crystalline solid after 
recrystallization from EtOH-H2O 1:1 v/v, yield 0.46 g (57 %). M.p. 197-200 
oC. TLC 
(9:1 CH2Cl2/MeOH), Rf = 0.63. 
1H NMR (CDCl3): 7.83 (s, 1H, pyrazole). 7.76-7.72 
(m, 6H, Ar), 7.58 (s, 1H, imidazole), 7.50 (t, J = 8.0 Hz, 2H, Ar), 7.40 (t,  J = 7.4 Hz, 
1H, Ar), 7.14 (s, 1H, imidazole), 6.90 (s, 1H, imidazole), 5.27 (s, 2H, CH2). 
13C-NMR 
(CDCl3): 149.1 (C, pyrazole), 139.3 (C, Ar), 137.0 (CH, imidazole), 132.8 (CH, 
imidazole), 132.6 (2 x CH, Ar), 130.2 (2 x CH, Ar), 129.7 (CH, imidazole), 128.3 (2 x 
CH, Ar), 128.1 (CH, pyrazole), 127.4 (2 x CH, Ar), 119.2 (CN), 118.8 (C, Ar), 116.8 
(C, pyrazole), 112.0 (C, Ar), 41.7 (CH2). Anal. Calcd for C20H15N5 (325.37): C, 
73.83; H, 4.65; N, 21.52. Found: C, 73.76; H,  4.69; N, 21.51. 
1-((1,3-Diphenyl-1H-pyrazol-4-yl)methyl)-1H-[1,2,4]triazole (8a). Prepared 
from 4-(chloromethyl)-1,3-diphenyl-1H-pyrazole (6a) (0.40 g, 1.5 mmol). Product 
obtained as a light yellow crystalline solid after recrystallization from methanol, yield 
0.115 g (26 %). M.p. 101-104 oC. TLC (3:1 petroleum ether/EtOAc), Rf = 0.06. 1H 
NMR (CDCl3): 8.29 (s, 1H, pyrazole), 8.07 (m, 2H, Ar), 7.77 (d, J = 7.7 Hz, 2H, 
Ar), 7.65 (d, J = 7.0 Hz, 2H, Ar), 7.42-7.50 (m, 5H, Ar), 7.34 (t, J = 7.5 Hz, 1H, Ar), 
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5.50 (s, 2H, CH2). 
13C-NMR (CDCl3): 151.7, 114.1 (2 x C, pyrazole), 139.6, 132.1 
(2 x C, Ar), 151.1, 142.6, 129.5, 128.9, 128.7, 128.6, 128.0, 127.0, 119.2 (13 x CH, 
Ar), 44.7 (CH2). Anal. Calcd for C19H15N5 (301.35): C, 71.74; H, 5.02; N, 23.23. 
Found: C, 71.97; H, 5.06; N, 23.35. 
1-((3-(4-Fluorophenyl)-1-phenyl-1H-pyrazole-4-yl)methyl)-1H-1,2,4-
triazole (8b). Prepared from 4-(chloromethyl)-3-(4-fluorophenyl)-1-phenyl-1H-
pyrazole (6b) (0.15 g, 0.52 mmol). Product obtained as a pale yellow crystalline solid 
after recrystallization from EtOH-H2O 1:1 v/v, yield 0.039 g (24 %). M.p. 114-118 
oC. TLC (3:1 petroleum ether/EtOAc), Rf = 0.06. 1H NMR (CDCl3): 8.09 (s, 1H, 
pyrazole), 8.03 (d, J = 7.7 Hz, 2H, triazole), 7.75 (d, J = 7.6 Hz, 2H, Ar), 7.61-7.64 
(m, 2H, Ar), 7.49 (t, J = 7.7 Hz, 2H, Ar), 7.35 (t, J = 7.4 Hz, 1H, Ar), 7.17 (t, J = 8.7 
Hz, 2H, Ar), 5.45 (s, 2H, CH2). 
13C-NMR (CDCl3): 164.0, 150.8, 139.5 (3 x C, Ar), 
150.8, 114.2 (2 x C, pyrazole), 152.1, 142.7, 129.8, 129.7, 129.5, 128.5, 127.1, 119.2, 
116.0, 115.8 (12 x CH, Ar), 44.4 (CH2). Anal. Calcd for C18H14FN5 (319.34): C, 
67.70; H, 4.42; N, 21.92. Found: C, 67.98; H,  4.00; N, 22.05. 
1-((3-(4-Chlorophenyl)-1-phenyl-1H-pyrazole-4-yl)methyl)-1H-1,2,4-
triazole (8c). Prepared from 4-(chloromethyl)-3-(4-chlorophenyl)-1-phenyl-1H-
pyrazole (6c) (0.61 g, 2 mmol). Product obtained as a pale yellow crystalline solid 
after recrystallization from ethanol, yield 0.27 g (40 %). M.p. 119-122 oC. TLC (3:1 
petroleum ether/EtOAc), Rf = 0.05. 1H NMR (CDCl3): 8.10 (s, 1H, pyrazole), 8.02 
(s, 2H, triazole), 7.74 (d, J = 7.8 Hz, 2H, Ar), 7.60 (d, J = 8.5 Hz, 2H, Ar), 7.44-7.51 
(m, 4H, Ar), 7.35 (t, J = 7.5 Hz, 1H, Ar), 5.55 (s, 2H, CH2). 
13C-NMR (CDCl3): 
150.5, 114.4 (2 x C, pyrazole), 139.5, 134.7, 120.7(3 x C, Ar), 150.2, 142.7, 129.6, 
129.2, 129.1, 128.6, 127.1, 119.2 (12 x CH, Ar), 44.3 (CH2). Anal. Calcd for 
C18H14ClN5 (335.79): C, 64.38; H, 4.20; N, 20.85. Found: C, 64.63; H,  3.81; N, 
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21.14. 
1((1-Phenyl-3-(p-tolyl)-1H-pyrazol-4-yl)methyl)-1H-1,2,4-triazole (8d). 
Prepared from 4-(chloromethyl)-1-phenyl-3-(p-tolyl)-1H-pyrazole (6d) (0.35 g, 1.24 
mmol). Product obtained as a yellow-orange crystalline solid after recrystallization 
from EtOH-H2O 1:1 v/v, yield 0.11 g (29 %). M.p. 128-130 
oC. TLC (3:1 petroleum 
ether/EtOAc), Rf = 0.14. 1H NMR (CDCl3): 8.14 (s, 1H, pyrazole), 8.04 (d, J = 5.6 
Hz, 2H, Ar), 7.76 (d, J = 8.1 Hz, 2H, Ar), 7.52 (d, J = 7.9 Hz, 2H, Ar), 7.48 (t, J = 7.8 
Hz, 2H, Ar), 7.33 (t, J = 7.2 Hz, 1H,Ar), 7.28-7.30 (m, 2H, Ar), 5.47 (s, 2H, CH2), 
2.43 (s, 3H, OCH3). 
13C-NMR (CDCl3): 151.8, 114.1 (2 x C, pyrazole), 139.7, 
138.6, 129.3 (3 x C, Ar), 151.6, 142.2, 129.6, 129.5, 128.4, 127.8, 126.9, 119.1 (12 x 
CH, Ar), 44.6 (CH2), 21.3 (CH3). Anal. Calcd for C19H17N5 (315.37): C, 72.36; H, 
5.43; N, 22.20. Found: C, 72.43; H,  5.43; N, 22.41. 
1-((3-(4-Methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)methyl)-1H-1,2,4-
triazole (8e). Prepared from 4-(chlorophenyl)-3-(4-methoxyphenyl)-1-phenyl-1H-
pyrazole (6e) (0.45 g, 1.5 mmol). Product obtained as an orange crystalline solid after 
recrystallization from EtOH-H2O 1:1 v/v, yield 0.21 g (43 %). M.p. 106-108 
oC. TLC 
(3:1 petroleum ether/EtOAc), Rf = 0.05. 1H NMR (CDCl3): 8.21 (s, 1H, pyrazole), 
8.05 (d, J = 7.7 Hz, 2H, Ar), 7.76 (d, J = 8.0 Hz, 2H, Ar), 7.57 (d, J = 8.7 Hz, 2H, 
Ar), 7.48 (d, J = 8.0 Hz, 2H, Ar), 7.33 (t, J = 7.4 Hz, 1H,Ar), 7.01 (d, J = 8.7 Hz, 2H, 
Ar), 5.47 (s, 2H, CH2), 3.88 (s, 3H, OCH3). 
13C-NMR (CDCl3): 160.0, 139.7, 124.7 
(3 x C, Ar), 151.6, 114.0 (2 x C, pyrazole), 151.9, 142.7, 129.6, 129.5, 129.2, 128.4, 
126.8, 119.2, 114.2 (12 x CH, Ar), 55.4 (CH3), 44.5 (CH2). Anal. Calcd for 
C19H17N5O (331.37): C, 68.87; H, 5.17; N, 21.12. Found: C, 68.87; H,  4.87; N, 
21.15. 
 24 
1-((3-(4-Bromophenyl)-1-phenyl-1H-pyrazol-4-yl)methyl)-1H-1,2,4-
triazole (8f). Prepared from (4-(chloromethyl)-3-(4-bromophenyl)-1-phenyl-1H-
pyrazole) (6f) (0.7 g, 2 mmol). Product obtained as a white crystalline solid after 
recrystallization from EtOH-H2O 1:1 v/v, yield 0.36 g (47 %). M.p. 144-146 
oC. TLC 
(9:1 CH2Cl2/MeOH), Rf = 0.68. 
1H NMR (CDCl3): 8.04 (s, 1H, pyrazole), 8.02 (s, 
2H, triazole), 7.74 (dd, J = 1.1, 8.7 Hz, 2H, Ar), 7.6 (dd, J = 1.9, 6.6 Hz, 2H, Ar), 7.54 
(s, 1H, Ar), 7.52-7.48 (m, 2H, Ar), 7.35 (t, J = 7.4 Hz, 1H, Ar), 5.45 (s, 2H, CH2). 
13C-NMR (CDCl3): 152.4 (CH, triazole), 150.5 (C, pyrazole), 142.8 (CH, triazole), 
139.5 (C, Ar), 132.2 (2 x CH, Ar), 129.7 (2 x CH, Ar), 129.6 (CH, Ar), 129.4 (2 x 
CH, Ar), 129.3 (CH, Ar), 128.6 (CH, pyrazole), 128.0 (C, pyrazole). 127.2 (2 x CH, 
Ar), 114.4 (C, Ar), 44.3 (CH2). Anal. Calcd for C18H14N5Br (380.24): C, 56.86; H, 
3.71; N, 18.42. Found: C, 56.48; H,  3.99; N, 18.43. 
1-((3-(4-Iodophenyl)-1-phenyl-1H-pyrazol-4-yl)methyl)-1H-1,2,4-triazole  
(8g). Prepared from (4-(chloromethyl)-3-(4-iodophenyl)-1-phenyl-1H-pyrazole) (6g) 
(0.8 g, 2 mmol). Product obtained as a white crystalline solid after recrystallization 
from EtOH-H2O 1:1 v/v, yield 0.4 g (46 %). M.p. 151-155 
oC. TLC (9:1 
CH2Cl2/MeOH), Rf = 0.13. 
1H NMR (CDCl3): 8.03 (s, 1H, pyrazole), 8.01 (s, 2H, 
triazole), 7.82 (dd, J = 1.8, 6.6 Hz, Ar), 7.74 (dd, J = 1.2, 8.7 Hz, 2H, Ar), 7.50 (t, J = 
8.0 Hz, 2H, Ar), 7.40 (d, J = 8.4 Hz, 2H, Ar), 7.35 (t, J = 7.4 Hz, 1H, Ar), 5.45 (s, 2H, 
CH2). 
13C-NMR (CDCl3): 152.4 (CH, triazole), 150.6 (C, pyrazole), 142.8 (CH, 
triazole), 139.5 (C, Ar), 138.0 (2 x CH, Ar), 131.7 (CH, Ar), 129.6 (2 x CH, Ar), 
129.4 (2 x CH, Ar), 128.7 (CH, Ar), 127.4 (CH, pyrazole), 119.2 (2 x CH, Ar), 114.4 
(C, pyrazole), 94.6 (C-I), 44.3 (CH2). Anal. Calcd for C18H14N5I (427.24): C, 50.60; 
H, 3.30; N, 16.39. Found: C, 50.87; H,  3.27; N, 16.38. 
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4-(4-((1H-Triazol-1-yl)methyl)-1-phenyl-1H-pyrazol-3-yl)benzonitrile  
(8h). Prepared from 4-(4-(chloromethyl)-1-phenyl-1H-pyrazol-3-yl)benzonitrile (6h) 
(0.5 g, 1.7 mmol). Product obtained as a white crystalline solid after recrystallization 
from EtOH-H2O 1:1 v/v, yield 0.23 g (42 %). M.p. 162-165 
oC. TLC (1:1 petroleum 
ether/EtOAc), Rf = 0.08. 1H NMR (DMSO-d6): 8.65 (s, 1H, triazole), 8.59 (s, 1H, 
triazole), 8.01-7.94 (m, 3H), 7.89 (d, J = 7.7 Hz, 2H, Ar), 7.53 (t, J = 8.0 Hz, 2H, Ar), 
7.37 (t, J = 7.4 Hz, 1H, Ar), 5.58 (s, 2H, CH2). 
13C-NMR (CDCl3): 152.1 (CH, 
triazole), 149.1 (C, pyrazole), 144.5 (CH, triazole), 139.5 (C), 137.3 (C), 133.2 (2 x 
CH), 130.9 (CH), 130.1 (2 x CH), 128.7 (2 x CH), 127.4 (CH), 119.2 (C), 119.1 (2 x 
CH), 116.8 (C), 111.2 (C), 43.5 (CH2).Anal. Calcd for C19H14N6 (326.36): C, 69.93; 
H, 4.32; N, 25.74. Found: C, 69.80; H,  4.23; N, 25.78. 
General method for the preparation of 1H-pyrazole-4-carboxamide. 
Carboxylic acid (9) (1 mmol) was dissolved in anhydrous DMF (4 mL/mmol), then a 
solution of 1,1’-carbonyldiimidazole (1.1 mmol) in dry DMF (1 mL/mmol) was added 
and the reaction stirred for 1 h. The reaction was cooled to 0 oC and a mixture of 1-(2-
ammonioethyl)-1H-imidazol-3-ium chloride (12) (1 mmol) with triethylamine (3 
mmol) in dry DMF (1 mL/mmol) was added and the mixture stirred at room 
temperature for 20 h. Once complete, ice cold H2O (50 mL/mmol) was added and the 
resulting yellow precipitate collected by filtration and washed with cold water and 
dried [15]. 
N-(2-(1H-Imidazol-1-yl)ethyl)-1,3-diphenyl-1H-pyrazole-4-carboxamide 
(13a). Prepared from 1,3-diphenyl-1H-pyrazole-4-carboxylic acid (9a) (0.42, 1.6 
mmol). Product obtained as a white solid after purification by gradient flash column 
chromatography, product eluted with EtOAc/MeOH 9:1 v/v, yield 0.24 g (40 %). 
M.p. 136-138 oC. TLC (9:1 EtOAc/MeOH), Rf  = 0.42. 
1H NMR (DMSO-d6): 8.90 
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(s, 1H, pyrazole), 8.37 (s, 1H, NH), 7.88 (d, J = 7.3 Hz, 2H, Ar), 7.79 (d, J = 6.5 Hz, 
2H, Ar), 7.65 (s, 1H, imidazole), 7.58 (t, J = 6.8 Hz, 2H, Ar), 7.43 (t, J = 8.2 Hz, 4H, 
Ar), 7.21 (s, 1H, imidazole), 6.92 (s, 1H, imidazole), 4.16 (s, 2H, CH2), 3.57 (d, J = 
4.6 Hz, 2H, CH2). 
13C-NMR (DMSO-d6):  162.9 (CO), 150.9 (C, pyrazole), 138.9, 
132.2 (2 x C, Ar), 129.9 (CH, pyrazole), 129.7 (CH, Ar), 129.6 (CH, Ar), 129.1 (CH, 
Ar), 128.4 (CH, Ar), 128.2 (CH, Ar), 128.2 (CH, Ar), 128.0 (CH, Ar), 127.9 (CH, 
Ar), 127.7 (CH, pyrazole), 126.9 (CH, Ar), 126.6 (CH, Ar), 118.8 (CH, Ar), 117.4 (C, 
pyrazole), 45.3, 40.0 (2 x CH2). Anal. Calcd for C21H19N5O (357.42): C, 70.57; H, 
5.36; N, 19.59. Found: C, 70.28; H,  5.19; N, 19.29. 
N-(2-(1H-Imidazol-1-yl)ethyl)-3-(4-fluorophenyl)-1-phenyl-1H-pyrazole-
4-carboxamide (13b). Prepared from 3-(4-fluorophenyl)-1-phenyl-1H-pyrazole-4-
carboxylic acid (9b) (0.25 g, 1.4 mmol). Product obtained as a white solid after 
purification by gradient flash column chromatography, product eluted with 
EtOAc/MeOH 9:1 v/v, yield 0.175 g (29 %). M.p. 158-160 oC. TLC (9:1 
CH2Cl2/MeOH), Rf = 0.2. 
1H NMR (CD3OD): 8.49 (s, 1H, pyrazole), 7.83 (d, J = 
7.7 Hz, 2H, Ar), 7.85 – 7.73 (m, 3H, Ar), 7.56 - 7.52 (Ψt, J = 7.6, 8.4 Hz, 2H, Ar), 
7.41 (t, J = 7.0 Hz, 1H, imidazole), 7.20 (s, 1H, imidazole), 7.19 - 714 (m, 2H, Ar), 
7.05 (s, 1H, imidazole), 4.28 (t, J = 6.0 Hz, 2H, CH2), 3.72 (t, J = 6.0 Hz, 2H, CH2). 
13C-NMR (CD3OD): 166.1 (CO), 165.4 (F-C), 163.5 (C, Ar), 152.4 (C, pyrazole), 
140.7 (C, Ar), 131.8, 131.7, 131.1, 129.9, 130.7, 128.9, 128.5 (13 x CH, Ar), 129.8 
(C, Ar), 118.1 (C, pyrazole), 47.2, 41.4 (2 x CH2). Anal. Calcd for C21H18FN5O: 0.3 
H2O (380.81): C, 66.60; H, 4.90; N, 18.31. Found: C, 66.57; H,  4.82; N, 17.99. 
N-(2-(1H-Imidazol-1-yl)ethyl)-3-(4-chlorophenyl)-1-phenyl-1H-pyrazole-
4-carboxamide (13c). Prepared from 3-(4-chlorophenyl)-1-phenyl-1H-pyrazole-4-
carboxylic acid (9c) (0.42 g, 1.4 mmol). Product obtained as a white crystalline solid 
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after recrystallization from acetonitrile, yield 0.11 g (19 %). M.p. 184-186 oC. TLC 
(9:1 CH2Cl2/MeOH), Rf = 0.13.
 1H NMR (CD3OD): 8.53 (s, 1H, pyrazole), 7.83 (d, 
J = 7.7 Hz, 2H, Ar), 7.72 (d, J = 8.5 Hz, 2H, Ar), 7.68 (s, 1H, imidazole), 7.55 (Ψt, J 
= 7.6, 8.4 Hz 2H, Ar), 7.44 – 7.39 (m, 3H, Ar), 7.18 (s, 1H, imidazole), 7.03 (s, 1H, 
imidazole), 4.25 (t, J = 6.0 Hz, 2H, CH2), 3.71 (t, J = 6.0 Hz, 2H, CH2). 
13C-NMR 
(CD3OD):  166.1 (CO), 152.2 (C, pyrazole), 140.7, 135.6, 132.3(3 x C, Ar), 131.2 
(CH, pyrazole), 131.1, 130.8, 129.4, 128.6, 120.5 (12 x CH, Ar), 118.3 (C, pyrazole), 
47.1, 41.4 (2 x CH2). Anal. Calcd for C21H18ClN5O: 0.1 H2O (393.66): C, 64.07; H, 
4.65; N, 17.79. Found: C, 63.92; H, 4.33; N, 17.76. 
N-(2-(1H-Imidazol-1-yl)ethyl)-1-phenyl-3-(p-tolyl)-1H-pyrazole-4-
carboxamide (13d). Prepared from 1-phenyl-3-(p-tolyl)-1H-pyrazole-4-carboxylic 
acid (9d) (0.47 g, 1.7 mmol). Product obtained as a white solid after purification by 
gradient flash column chromatography, product eluted with EtOAc/MeOH 9:1 v/v, 
yield 0.034 g (6 %). M.p. 76-80 oC. TLC (9:1 CH2Cl2/MeOH), Rf = 0.20.
 1H NMR 
(CD3OD):  8.50 (s, 1H, pyrazole), 7.81 (d, J = 7.7 Hz, 2H, Ar), 7.69 (s, 1H, 
imidazole), 7.59 (d, J = 8.1 Hz, 2H, Ar), 7.53 (Ψt, J = 7.7, 8.3 Hz, 2H, Ar), 7.39 (t, J 
= 7.5 Hz, 1H, Ar), 7.24 (d, J = 8.0 Hz, 2H, Ar), 7.17 (s, 1H, imidazole), 7.03 (s, 1H, 
imidazole), 4.23 (t, J = 6.0 Hz, 2H, CH2), 3.68 (t, J = 6.0 Hz, 2H, CH2), 2.45 (s, 3H, 
CH3).
 13C-NMR (CD3OD):  165.6 (CO), 152.50 (C, pyrazole), 139.98, 139.1 (2 x C, 
Ar), 130.4 (CH, pyrazole), 129.9, 129.2, 128.3, 119.7 (12 x CH, Ar), 129.8 (C, Ar), 
117.4 (C, pyrazole), 46.4, 40.6 (2 x CH2), 20.6 (CH3). Anal. Calcd for C22H21N5O 
(371.44): C, 71.14; H, 5.70; N, 18.85. Found: C, 70.87; H,  5.74; N, 18.67. 
N-(2-(1H-Imidazol-1-yl)ethyl)-3-(4-methoxyphenyl)-1-phenyl-1H-
pyrazole-4-carboxamide (13e). Prepared from 3-(4-methoxyphenyl)-1-phenyl-1H-
pyrazole-4-carboxylic acid (9e) (0.4 g, 1.4 mmol). Product obtained as a yellow solid 
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after purification by gradient flash column chromatography, product eluted with 
EtOAc/MeOH 9:1 v/v, yield 0.18 g (32 %). M.p. 108-112 oC. TLC (9:1 
CH2Cl2/MeOH), Rf = 0.60.
 1H NMR (CD3OD):  8.51 (s, 1H, pyrazole), 7.83 (d, J = 
7.7 Hz, 2H, Ar), 7.66 (s, 1H, imidazole), 7.55 (Ψt, J = 7.6, 8.4 Hz 2H, Ar), 7.42 – 
7.27 (m, 4H, Ar/imidazole), 7.16 (s, 1H, imidazole), 7.01 – 6.98 (m, 2H, Ar), 4.25 (t, 
J = 6.0 Hz, 2H, CH2), 3.86 (s, 3H, OCH3), 3.71 (t, J = 6.0 Hz, 2H, CH2).
 13C-NMR 
(CD3OD): 166.3 (CO), 161.1 (C, Ar), 152, 9 (C, pyrazole), 140.8, 134.8 (2 x C, Ar), 
131.2 (CH, pyrazole), 130.7, 130.5, 129.2, 128.5, 122.1, 120.9, 115.4, 115.2 (12 x 
CH, Ar), 118.5 (C, pyrazole), 55.8 (OCH3), 47.1, 41.5 (2 x CH2). Anal. Calcd for 
C22H21N5O2: 0.2 H2O (391.04): C, 67.57; H, 5.51; N, 17.91. Found: C, 67.21; H, 5.25; 
N, 17.56. 
 
CYP121A1 Spectral binding assays for ligand KD determination. 
CYP121A1 protein was expressed and purified as described previously.14 Ligand 
binding assays were performed by spectrophotometric titration using a Cary 60 UV-
visible scanning spectrophotometer (Agilent, UK) and a 1 cm path length quartz 
cuvette, recording spectra between 250 and 800 nm. Titrations were typically done 
with 3-5 μM CYP121A1 at 28 oC in 100 mM potassium phosphate (KPi) buffer, 200 
mM KCl, pH 7.85 with 0.004% Triton X-100. Ligand stock solutions were prepared 
in dimethylsulfoxide (DMSO). Ligands were added in small volumes (typically 0.05-
0.2 µL aliquots) from concentrated stock solutions to the protein in a 1 mL final 
volume. Spectral measurements were taken before ligand addition, and following 
addition of each aliquot of ligand until no further spectral change occurred. Difference 
spectra at each stage in the titration were obtained by subtraction of the initial ligand-
free enzyme spectrum from subsequent spectra collected after each addition of ligand. 
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From the difference spectra, a pair of wavelengths were identified and defined as the 
absorbance maximum (Apeak) and minimum (Atrough). The overall absorbance change 
(Amax) was calculated by subtracting the Atrough value from the Apeak value for each 
spectrum collected after a ligand addition. Graphs of Amax against [ligand] were 
plotted for each titration. Titrations were done in triplicate and the final Kd value 
presented was determined as the average value across the three sets. The Kd values 
were determined by fitting the data using either a standard hyberbolic function 
(Equation 1) or the Hill equation (Equation 2) using Origin software (OriginLab, 
Northampton, MA). 
Aobs = (Amax*L/(Kd+L))                            (Equation 1) 
In Equation 1 (the standard hyperbolic function, the Michaelis-Menten function 
adapted for ligand binding), Aobs is the observed absorbance change at ligand 
concentration L, Amax is the maximal absorbance change observed at apparent ligand 
saturation, and Kd is dissociation constant for the binding of the ligand (the substrate 
concentration at which Aobs = 0.5 x Amax). 
Aobs = (Amax × L
n)/(Kn+Ln)           (Equation 2) 
In Equation 2 (the sigmoidal Hill equation), Aobs is the observed absorbance change at 
ligand concentration L, Amax is the absorbance change at apparent ligand saturation, K 
is the apparent dissociation constant, and n is the Hill coefficient, a value describing 
the apparent extent of cooperativity observed in ligand binding. 
 
5.5 Antimycobacterial Activity Assay 
M. tuberculosis H37Rv was grown in 7H9 liquid medium with 10 % Middlebrook 
OADC Growth Supplement enrichment (BBL/Becton-Dickinson, Sparks, MD, USA). 
The bacterial growth occurred at 37 °C until  the mid-log phase was reached (OD600nm 
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= 0.4-0.6). After this period, the bacterial suspensions were prepared as described 
below and REMA assays were performed. The anti-M. tuberculosis activity of the 
compounds was determined by the REMA (Resazurin Microtiter Assay) method.15 
Stock solutions of the tested compounds (10 µg/mL) were prepared in DMSO and 
diluted in Middlebrook 7H9 broth supplemented with 10% OADC. 
The microdilution of the compounds was performed in 96-well plates to obtain final 
compound concentration ranges of 0.39-100 µg/mL. Rifampicin in the concentration 
range between 0.004-1 µg/mL was added as control. Bacterial suspensions were 
prepared and their turbidities adjusted to match the optical density of McFarland no. 1 
standard. After a further dilution of 1:20 in Middlebrook 7H9 broth supplemented 
with OADC, 100 µL of the inoculum was added to each well of the 96-well plate. 
Cultures were incubated for 7 days at 37 °C, and 30 µL of 0.01% resazurin was 
added. Wells were read after 24 h for colour change and measured as the fluorescence 
(excitation/emission of 530/590 nm filters, respectively) in a microfluorimeter. The 
MIC was defined as the lowest concentration resulting in 90 % inhibition of M. 
tuberculosis growth. The presented results are from two independent experiments. 
Molecular Modeling and Docking. Docking studies were performed using 
the MOE16 program and Mtb CYP121A1 co-crystallized with fluconazole (pdb 2IJ7). 
All minimisations were performed with MOE until a RMSD gradient of 0.01 
Kcal/mol/A with MMFF94 forcefield and partial charges were automatically 
calculated. The charge of the heme iron at physiological pH was set to 3+ (geometry 
d2sp3) through the atom manager in MOE. The Alpha Triangle placement, which 
derives poses by random superposition of ligand atom triplets through alpha sphere 
dummies in the receptor site, was chosen to determine the poses. The London G 
scoring function estimates the free energy of binding of the ligand from a given pose. 
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Refinement of the results was done using the MMFF94 forcefield, and rescoring of 
the refined results using the London G scoring function was applied. The output 
database dock file was created with different poses for each ligand and arranged 
according to the final score function (S), which is the score of the last stage that was 
not set to zero. 
Crystallography studies on CYP121A1. Untagged CYP121A1 protein and 
crystals were prepared as previously reported, with the following adaptations.14 
Crystals were prepared using a Mosquito pipetting robot (Molecular Dimensions, 
Newmarket, UK) in 800 nL drops with protein-to-mother liquor at a ratio of 1:1, by 
vapour diffusion in 1.5–2.1 M ammonium sulfate and 0.1 M sodium MES, or 
Cacodylate from pH 5.5–6.15. Co-crystals were prepared following incubation with 2 
mM ligand prepared in DMSO. Protein solutions were centrifuged at 14,000 rpm for 
20 mins at 4 °C immediately before crystallogenesis. Ligand soaks were also carried 
out either by directly dissolving solid ligand to saturation, or by the addition of a 2–5 
mM ligand solution in DMSO to the mother liquor, and soaking was carried out for a 
minimum period of 24 h. Crystals were immersed in mother liquor supplemented with 
10-30% oil as cryoprotectant, and cryoprotected and flash-cooled in liquid nitrogen. 
Data were collected on beamline i02 (wavelength 0.9795 Å) at the Diamond Light 
Source Facility (Harwell, UK). The diffraction data were reduced, scaled and merged 
using XDS or Xia2.18,19 Structures were refined using PHENIX20 with the native 
CYP121A1 structure (PDB 1N40)14 as the starting model. Structural rebuilding and 
validation were performed with COOT,21 Molprobity22 and PDB REDO.23  
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